Roxanol and Thalidomide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Roxanol (morphine sulfate) and Thalidomide (thalidomide). Common drug interactions include osteolysis among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Roxanol and Thalidomide. It is created by eHealthMe based on reports of 53 people who take the same drugs from the FDA, and is updated regularly.

What is Roxanol?

Roxanol has active ingredients of morphine sulfate. eHealthMe is studying from 807 Roxanol users. Check the latest studies of Roxanol.

What is Thalidomide?

Thalidomide has active ingredients of thalidomide. eHealthMe is studying from 16,473 Thalidomide users. Check the latest studies of Thalidomide.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Aug, 27, 2026

53 people who take Roxanol and Thalidomide together, and have interactions are studied.

Roxanol and Thalidomide drug interactions.

What are the common drug interactions of Roxanol and Thalidomide, by gender? *:

female:

  1. Osteolysis (dissolution of bone)
  2. Pain
  3. Pain in jaw
  4. Blood lactate dehydrogenase increased
  5. Injury
  6. Pain in extremity
  7. Pneumonia
  8. Thrombocytopenia (decrease of platelets in blood)
  9. Anaemia (lack of blood)
  10. Back pain

male:

  1. Anxiety
  2. Pain
  3. Decreased appetite
  4. Constipation
  5. Pleural effusion (water on the lungs)
  6. Discomfort
  7. Emotional distress
  8. Fatigue (feeling of tiredness)
  9. Spinal cord compression
  10. Cardiomegaly (increased size of heart than normal)

What are the common drug interactions of Roxanol and Thalidomide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Asthma
  2. Chest pain
  3. Headache (pain in head)
  4. Oedema lower limb (fluid collection in tissue of lower leg)
  5. Pain in limb

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Pain
  4. Pain in jaw
  5. Spinal compression fracture (fracture due to spinal compression on bone)
  6. Bone disorder
  7. Loose tooth
  8. Mastication disorder (disease of chewing food)
  9. Cardiomegaly (increased size of heart than normal)
  10. Decreased appetite

50-59:

  1. Hypophagia (reduced food intake)
  2. Intervertebral disc degeneration (spinal disc degeneration)
  3. Osteonecrosis of jaw (death of bone of jaw)
  4. Pleural fibrosis (formation of fibrous tissue in lung)
  5. Sciatica (a set of symptoms including pain caused by general compression or irritation of one of five spinal nerve roots of each sciatic nerve)
  6. Arthropathy
  7. Haematochezia (passage of stools containing blood)
  8. Myofascial pain syndrome (a painful condition that affects the muscles and the sheath of the tissue)
  9. Post laminectomy syndrome
  10. Spondylitis (an inflammation of the vertebra with spinal cord involvement)

60+:

  1. Anxiety
  2. Blood lactate dehydrogenase increased
  3. Anaemia (lack of blood)
  4. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  5. Azotaemia (excess of urea or other nitrogenous compounds in the blood)
  6. Back pain
  7. Blood creatinine increased
  8. Bone disorder
  9. Bone fissure
  10. Bruxism (habitual grinding of the teeth, typically during sleep)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 24 people, 45.28%
  2. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 13 people, 24.53%
  3. Bone Density Decreased: 13 people, 24.53%
  4. Pain: 11 people, 20.75%
  5. Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 11 people, 20.75%

* Approximation only. Some reports may have incomplete information.

Do you take Roxanol and Thalidomide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Roxanol and Thalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Roxanol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Thalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Roxanol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Thalidomide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on morphine sulfate and thalidomide (the active ingredients of Roxanol and Thalidomide, respectively), and Roxanol and Thalidomide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: